Sensei announces clinical supply agreement with Regeneron for Libtayo

Sensei Biotherapeutics (SNSE) announced a clinical supply agreement with Regeneron (REGN) for its anti-PD1 therapy Libtayo. The supply agreement supports the evaluation of SNS-101, a conditionally active VISTA-blocking antibody, in combination with Libtayo in a Phase 1/2 trial in solid tumors. Sensei is on track to submit an Investigational New Drug application for SNS-101 in or before April 2023 and the trial is expected to commence in 2023 pending regulatory clearance. "We are excited for the opportunity to work with Regeneron on our planned clinical trial of SNS-101, which has demonstrated strong anti-tumor activity in combination with PD-1 inhibition in preclinical studies. We look forward to exploring the potential of SNS-101 to inhibit tumor growth across a range of indications," said John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics. "We have built a robust preclinical data package supporting the biological rationale for our pH-sensitive approach, which we believe offers both safety and efficacy advantages over pH-independent VISTA antibodies, including the potential to avoid poor pharmacokinetics from target-mediated drug disposition and lower the risk of cytokine release syndrome." Under the terms of the agreement, Sensei will sponsor and fund the planned clinical trial and Regeneron will provide Libtayo. Sensei will maintain global development and commercial rights to SNS-101. Regeneron develops and commercializes Libtayo globally.